- Home
- HRMY vs BCAT Comparison
HRMY vs BCAT Comparison
Compare HRMY & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- BCAT
- Stock Information
- Founded
- HRMY 2017
- BCAT 2020
- Country
- HRMY United States
- BCAT United States
- Employees
- HRMY N/A
- BCAT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- BCAT Finance/Investors Services
- Sector
- HRMY Health Care
- BCAT Finance
- Exchange
- HRMY Nasdaq
- BCAT Nasdaq
- Market Cap
- HRMY 1.6B
- BCAT 1.5B
- IPO Year
- HRMY 2020
- BCAT N/A
- Fundamental
- Price
- HRMY $34.05
- BCAT $14.84
- Analyst Decision
- HRMY Strong Buy
- BCAT
- Analyst Count
- HRMY 8
- BCAT 0
- Target Price
- HRMY $52.88
- BCAT N/A
- AVG Volume (30 Days)
- HRMY 701.6K
- BCAT 308.8K
- Earning Date
- HRMY 05-06-2025
- BCAT 01-01-0001
- Dividend Yield
- HRMY N/A
- BCAT 9.38%
- EPS Growth
- HRMY 13.13
- BCAT N/A
- EPS
- HRMY 2.62
- BCAT 1.43
- Revenue
- HRMY $744,852,000.00
- BCAT N/A
- Revenue This Year
- HRMY $20.06
- BCAT N/A
- Revenue Next Year
- HRMY $18.40
- BCAT N/A
- P/E Ratio
- HRMY $13.10
- BCAT $11.41
- Revenue Growth
- HRMY 20.62
- BCAT N/A
- 52 Week Low
- HRMY $26.47
- BCAT $13.67
- 52 Week High
- HRMY $41.61
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- BCAT 61.95
- Support Level
- HRMY $29.82
- BCAT $14.60
- Resistance Level
- HRMY $30.61
- BCAT $14.49
- Average True Range (ATR)
- HRMY 1.12
- BCAT 0.17
- MACD
- HRMY 0.74
- BCAT 0.10
- Stochastic Oscillator
- HRMY 92.78
- BCAT 96.88
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.